1,496 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Buy
Article Searches
Sutro Biopharma Prepares Terms For $75 Million U.S. IPO https://seekingalpha.com/article/4207653-sutro-biopharma-prepares-terms-75-million-u-s-ipo?source=feed_sector_healthcare Sep 21, 2018 - Sutro Biopharma intends to raise at least $75 million from the sale of its common stock in a U.S. IPO.The firm is advancing a pipeline of protein therapeutics for various forms of cancer.STRO has rece
Arvinas Holding Prepares Terms For $100 Million IPO https://seekingalpha.com/article/4207415-arvinas-holding-prepares-terms-100-million-ipo?source=feed_tag_ipo_analysis Sep 20, 2018 - Arvinas Holding aims to sell $100 million of its common stock in a U.S. IPO.The firm is advancing a pipeline of drug candidates for the treatment of various cancers.Although still a very early stage c
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ... http://www.gurufocus.com/news/742149/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-196-million-of-shares Sep 19, 2018 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19.6 million of Shares, Stocks: MRK, release date:Sep 19, 2018
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication http://www.zacks.com/stock/news/323898/jj-files-nda-for-erdafitinib-in-urothelial-cancer-indication?cid=CS-ZC-FT-323898 Sep 19, 2018 - Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
Accenture, Merck & Amazon AWS Partner for Cloud Platform http://www.zacks.com/stock/news/323697/accenture-merck-amazon-aws-partner-for-cloud-platform?cid=CS-ZC-FT-323697 Sep 18, 2018 - Accenture's (ACN) latest partnership is likely to boost its Products segment.
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? http://www.zacks.com/stock/news/323475/can-pfizer-pfe-bank-on-bavencio-for-long-term-growth?cid=CS-ZC-FT-323475 Sep 18, 2018 - Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds https://seekingalpha.com/article/4206435-daily-pharma-scoop-fibrogen-fast-tracked-dr-reddys-entry-bristol-myers-succeeds?source=feed_sector_healthcare Sep 15, 2018 - FibroGen's pamrevlumab fast tracked for IPF.Dr. Reddy’s generic launch.Bristol-Myers Squibb succeeds in mid-stage trials.
Are Options Traders Betting on a Big Move in Merck (MRK) Stock? http://www.zacks.com/stock/news/323056/are-options-traders-betting-on-a-big-move-in-merck-mrk-stock?cid=CS-ZC-FT-323056 Sep 14, 2018 - Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.
Your Cancer Highlight: Merck Tightening Its Grips On Front-Line Lung Cancer https://seekingalpha.com/article/4206218-cancer-highlight-merck-tightening-grips-front-line-lung-cancer?source=feed_sector_healthcare Sep 14, 2018 - Merck's application for first-line pembrolizumab in a wider patient population has now been accepted.If approved, it could change the dimension of the market for non-small cell lung cancer.What does t
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus http://www.zacks.com/stock/news/323144/pharma-stock-roundup-azns-leukemia-drug-wins-fda-nod-mrks-keytruda-in-focus?cid=CS-ZC-FT-323144 Sep 14, 2018 - Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

Pages: 123456...150

Page 1>

Related Companies

Name Exchange Price Mkt Cap
NVS Novartis AG NYSE $85.13 $197.65B
ABBV AbbVie Inc. NYSE $95.37 $144.42B
PFE Pfizer, Inc. NYSE $43.01 $252.13B
ABT Abbott Laboratories NYSE $67.67 $118.71B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Merck & Company